{"name":"Genocea Biosciences, Inc.","slug":"genocea-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":308000,"revenueGrowth":1440,"grossMargin":0,"rdSpend":39020000,"netIncome":-33196000,"cash":55967000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2014"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GEN-004 Mid Dose","genericName":"GEN-004 Mid Dose","slug":"gen-004-mid-dose","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GEN-004 with Aluminum Hydroxide Adjuvant","genericName":"GEN-004 with Aluminum Hydroxide Adjuvant","slug":"gen-004-with-aluminum-hydroxide-adjuvant","indication":"Melanoma (in combination with checkpoint inhibitors)","status":"phase_2"}]}],"pipeline":[{"name":"GEN-004 Mid Dose","genericName":"GEN-004 Mid Dose","slug":"gen-004-mid-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GEN-004 with Aluminum Hydroxide Adjuvant","genericName":"GEN-004 with Aluminum Hydroxide Adjuvant","slug":"gen-004-with-aluminum-hydroxide-adjuvant","phase":"phase_2","mechanism":"GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells.","indications":["Melanoma (in combination with checkpoint inhibitors)","Other solid tumors expressing shared tumor-associated antigens"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPOFBJY01MaEVycnVmdW85Qjg5TklSVkQ3Z1d1OGlvYnpNTGVXcDlsN0lreE5Gc3hXeXMxMWNtaUJuMFc0N2x0UlZKLUNQcXFzY2VCeHp4U2R4akhvbDhUNTFVZEgzWFN6Mk1kY2ZGTnE1TWNqRVRnNlUyTmdLeDV4MnUxVjhGWW5pNmpZdlo4MWFxWkx0LTZzZWh5OUhrZEp5aUp1dWtZc19VWnJIQmJJd0RNYXE?oc=5","date":"2026-03-04","type":"pipeline","source":"BioSpace","summary":"Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace","headline":"Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxOa01QdWp6ZndUT2xyT01KSUNBTHcxNGhkampLR2stYnkzUjE3NFBxcFRtOXQ0NE93QXhxMWxjVHM4c0tkZWFDYi1EcDBSSk43SVBzdE1GMVdiZy0xVFd5UUFPeW1xaFc1RWNJWERCYUk4N2k3Tjk4WTJ3T3lWR1I5WlFSeWpnaDdDWXRpVTVmMWE2dWhyTnNndW9QdnM3Q3ZvWHRnM1NWcDJMRmc0WXFCOFg1NWFXMUtJR1dwMEV1RkVON0lFQWM3c0JfQVpyd1RzWlZuYi1vVFNEQXc1XzdnaGN3QU5OUGo3NkVDWENrdjl6YjZKMTRrOVdqQ2RlUVJwYlMxdVBzNEVQbEhYX0FYcjZ2LV9jcndydk9RNmNXUHRpTUVKU1J5TU1uRF9oZmt2c0hhYW5hT2JxNkJPZ1JCcQ?oc=5","date":"2025-12-11","type":"pipeline","source":"Business Wire","summary":"Neoantigen Cancer Vaccines Market to Nearly Triple by 2032 Reaching $1.19 Billion: Analysis of Key Opportunities and 26 Industry Players - ResearchAndMarkets.com - Business Wire","headline":"Neoantigen Cancer Vaccines Market to Nearly Triple by 2032 Reaching $1.19 Billion: Analysis of Key Opportunities and 26 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9waDNHdGtvdmtZbFlsY2xpajBWV29mdDJtemttWnZjM09SMm5GYjlYZEtiUVd1QXRtSmhTZkpVeFZYREt3TFhGWmh5QmJSYmV0UWRabmZrazBDbVBSY1JOYXdwaktRS3o1NENKR2JXRUNHRjZ6akE2Zmlzd1g?oc=5","date":"2023-01-03","type":"pipeline","source":"Fierce Biotech","summary":"Layoff Tracker: Layoffs strike 119 companies in 2022 - Fierce Biotech","headline":"Layoff Tracker: Layoffs strike 119 companies in 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5WTml6RWlkdFNlcElfTFRnUFpsZURTWU9tWmo5UlBEemg3M29yYUlDeHY4bEVJbjQ0QVJtaHJFUnAxRkdReTdzRndwTnktNF84cGw5VmVLTTBZNmEzS0I1TFp0bkpiSXBRdEZrVA?oc=5","date":"2022-11-21","type":"pipeline","source":"Fierce Biotech","summary":"The 2022 Biotech Graveyard - Fierce Biotech","headline":"The 2022 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9Iby15MHZTRlhBYi1UZDlDS1FibWhwdC1pdGdfbW1EeEZ1aDdpbW9oVmpReWRkb1doQ2M0WklJY0xxWHhlY0ExN2M4UzVrS3B2SjV0VTVxMTR0NEVlVlc1S0VEX3dsOUY3T0QzUHdjUk1SekdJSmc?oc=5","date":"2022-07-31","type":"pipeline","source":"Straits Research","summary":"Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2033 - Straits Research","headline":"Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOcHJuZkpEaERaMFQzcktVVE9pXzJidE9VTE40cXc2bW1xVWZQdEFtZWJZSkg2U3BtWEREem53TFhPRFpvTk9yVUZqeHJJR0FCVVFqRHdWZFZjTWhOcXdiME5EV3VlMVdmUlAwVS1xYTBPdi1YaTZLb2FTRHFLU3ZlZ1NwT0NCNl9VTFJsalVHZmRiZw?oc=5","date":"2022-05-25","type":"pipeline","source":"BioPharma Dive","summary":"A cash-strapped biotech winds down operations - BioPharma Dive","headline":"A cash-strapped biotech winds down operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOYTAwWUJaSEVabDZuUnpVWloxVnpMdHkzT0RfMU1JZ1Vkc1hFWEpwU3pKNkx3aGRKMUh0WjVCckNkZkN6VzhBUnExNWhFS1R2ZWo0blBGeDNjaGJuOGFEUDJ3OXJ3b3NBWDNzS3p2TnNEZ0ZlWDdyQ3BQbEgzQ19DcmRzWVhiSVppcElyUS1nc0wtTTZ0VDFiTVVwSU1rdw?oc=5","date":"2022-05-24","type":"deal","source":"Fierce Biotech","summary":"Genocea closes up shop after failing to find a buyer, delists from Nasdaq - Fierce Biotech","headline":"Genocea closes up shop after failing to find a buyer, delists from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNU19zQ0VIemdybkM0UTd2bXg0SERnQzJSbTFwNkhyTDdMQVBLNm5SOGVzQnJYUHhfV2VwbDhKTkpBWnF0NlBOQzVDVDdIS1EtVkJwVzBvSnJ2OXhDaWFHeGdJV055WUxSckU5X0VZcVdoWnZTbDZFcXpMSXFHekdNWkdGblhZV1BlY01rMGVFZWoyY0xBQS1LRXdIeVBRMWtySE5Z?oc=5","date":"2022-05-24","type":"pipeline","source":"The Business Journals","summary":"Three weeks after layoffs, Genocea shuts down entirely - The Business Journals","headline":"Three weeks after layoffs, Genocea shuts down entirely","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQTB1Vnl4NHA3aDJHbmF5ci1RZHFYMDVfSlJUQTFXQ3JocTV6Nm9pSUFBOVZkdWdxQU9yTFZyU1R3RHl3Z1E2QmxFSUljZTJwZmkzN0EzajJyekJmYTJBbXpYTXJSWXM3aDB4OU9Ga2NEOWFkR3NQOG41UWJIY0x0aVRORURCaEpKZm1fRjBCVTZYRGVoR1pZTEc4anRNNndfN3U4amNyLVhPcDd2QVNNU2NpRzBwUVVsa2dIZjVwQlZiOU1MbUZYeEhGRmZrcGlPSm5NVkxlbk5PUQ?oc=5","date":"2022-01-24","type":"pipeline","source":"Business Wire","summary":"Expansion Therapeutics Names Sudhir Rao Senior Vice President of Business Development - Business Wire","headline":"Expansion Therapeutics Names Sudhir Rao Senior Vice President of Business Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNVkFNN1gwR01BRmJzTWdvR296YU1jRWxvNWFodkFwTnlYWHFzcmctank2RUplLVNKcDRRcjBJb0NscDhhNC1ZZ0RHU3ptVzVLTVZ1RXp6LVEtVWNaZzJuOVVlWjRjdmZrdGZYTllWbnRaeTNjMnFpRld6V2xPVkk4dTlsbmhnSHJHSFU5b0pFcGYzaWVza3E4?oc=5","date":"2021-10-19","type":"pipeline","source":"The Healthcare Technology Report.","summary":"The Top 25 Women Leaders in Biotechnology of 2021 - The Healthcare Technology Report.","headline":"The Top 25 Women Leaders in Biotechnology of 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOajJ0VHdOVlMzaERmbkYzMEtzUVFaRE5PdUptOFpqRFlFcFhSdTlIWjl3aFhpVjZiZkRVa1M0OXdLYmpsYU9lTVJJOVRUOWRYOGwzcFAyT2w1cnV5VFlub0pLV0hMU3lVZEl0Sy1nOTZmV1BYVEhJRU9DdzFmR1VzX1FKdXZndllKTU4zcXpzYTNmNmkyT0t2bGNlc1Q?oc=5","date":"2021-09-22","type":"deal","source":"WSJ","summary":"Cancer Ordeal Inspired a Pharmaceutical Career - WSJ","headline":"Cancer Ordeal Inspired a Pharmaceutical Career","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNdklHT2ZFTFl0UFZmYjRMVjRORW1SYUFEUjYydUxYNlpSNC05NWVmOWkzdXBpWjlKVi13VWJhaHR0NFVTTUZjMTA2WVhIcUpBUXJxZ0RvS2RfeUV2RGo5aUFveGZYVkFBTFlpd3llaVNGdVpyVTRVZHgzTGVPN1ZyeTRhTFNnTTg4ODJNZWJqOC11Zw?oc=5","date":"2019-08-24","type":"pipeline","source":"Yahoo Finance","summary":"10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance","headline":"10 Biopharmaceutical Companies Trying To Cure Cancer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":308000,"revenuePeriod":"2014-12-31","revenueHistory":[{"value":308000,"period":"2014-12-31"},{"value":20000,"period":"2013-12-31"},{"value":224000,"period":"2013-09-30"},{"value":228000,"period":"2013-06-30"},{"value":259000,"period":"2013-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":39020000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-33196000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":55967000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}